C
Central Texas Neurology Consultants (CTNC) | Round Rock, TX
Research site
(Unclaimed)
Site insights
Top conditions
Top treatments
EYE103
Ranibizumab
Aflibercept
K0706
EYE201
Curious how this site stacks up to its peers?
Data sourced from clinicaltrials.gov
Work at this site?
CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.
Active trials
3 of 7 total trials
EYE-RES-104 is a randomized, dose-masked study of intravitreal remigromig (EYE103) in participants with neovascular age-related macular degeneration...
Enrolling
Neovascular Age-Related Macular Degeneration (NVAMD)
Branch Retinal Vein Occlusion (BRVO)
Drug: Aflibercept 2.0 mg
Drug: Remigromig
EYE-RES-103 is a randomized, double masked pivotal study to evaluate the efficacy and safety of 2 dose levels of remigromig (EYE103) in comparison wi...
Active, not recruiting
Diabetic Macular Edema (DME)
Drug: Ranibizumab
Drug: Remigromig
EYE-RES-102 is a randomized, double masked pivotal study to evaluate the efficacy and safety of 2 dose levels of remigromig (EYE103) in comparison wi...
Active, not recruiting
Diabetic Macular Edema (DME)
Drug: Remigromig
Drug: Ranibizumab
Trial sponsors
E
O
Clinical trials
Research sites
Resources
Legal
© Copyright 2026 Veeva Systems